SBIR/STTR Research Award

SBIR Phase II: Sprayable Reversible Hemostat for Treatment of Non-Compressible Hemorrhage

Award identifier 63faa915841edc459ff4fceb6f0562e935663411ee7b4b601b6f6864a7125a6cAwarding agency National Science Foundation

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Remedium Technologies, Inc.
Proposal award date
2013-02-01
Contract end date
2015-01-31
UEI
HFL9S8BZK9N5
Solicitation number
Not reported
Topic code
BC

Research abstract

This Small Business Innovation Research (SBIR) Phase II project aims to develop a sprayable foam hemostat for treatment of non-compressible hemorrhage, which is the leading cause of death (~90%) for bleeding-related trauma. The foam material is based on the biopolymer chitosan; a modification to this polymer with novel hydrophobic grafts allows the material to clot blood much more rapidly and adhere to tissue more strongly than the unmodified version. Also, a complementary cyclodextrin-based technology is able to reverse the hemostatic action of the modified chitosan on demand. The biopolymer is packaged into aluminum hand-held canisters with liquefied propellant and expelled via mechanical actuator creating a foam which is able to expand into irregularly shaped cavities. The desired outcome of the project is to develop a working prototype of the canister containing an optimized modified chitosan with respect to hydrophobic grafting density and hydrophobe length. Foam formulations will be tested for clotting and reversibility in vitro via dynamic and steady shear rheology studies in the presence of blood and in vivo using non-compressible bleeding models in pigs. Biocompatibility testing and tissue histology studies will be performed to determine the safety profile of the optimized formulations. The broader impact/commercial potential of this project falls in the arena of battlefield and trauma medicine. Foams are the future of acute wound treatment on the battlefield and in emergency medical services. Severe bleeding, especially internal bleeding, is not easily treated with a spatially contained product, such as a bandage. Furthermore, correct bandage placement on an acute wound requires a great deal of skill and experience. However, a sprayable foam is very user friendly and allows potential for adequate self-application or application by an unskilled 'buddy' for a wide range of hemorrhage types. Thus, we envision our chitosan foam as a necessary supply in the soldier's backpack, the emergency room and the home first aid kit. This vision is a viable economic prospect because the material is low cost, lightweight and highly durable even in extreme ambient conditions. Additionally, the reversibility provided by the complementary cyclodextrin system provides a streamlining tool for the trauma surgeon. Removal of hemostatic material and precise indentification of the injury site are necessary tasks in the operating room which are made much easier by this unique technological feature.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2012–2013). Reported award amounts total $650,000. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.